Have you and your family had your flu shot? It's more important than ever this year! Schedule via MyChart or call for an appointment in SF, the East Bay or San Mateo.

About me

Dr. Sue Yom is an expert in the radiation treatment and management of head, neck and lung cancers.

In her research, Yom studies chemoradiation (a combination of chemotherapy and radiation) for these cancers. She also investigates image-guided radiation therapy and ways to reduce toxic effects using focused radiation techniques, emerging biological agents and radiation protectants.

Yom earned her medical and doctoral degrees at the University of Pennsylvania. She completed a residency in radiation oncology at the MD Anderson Cancer Center.

Yom has received numerous awards recognizing her commitment to patient care and patient-oriented research.

  • Education

    University of Pennsylvania School of Medicine, 2002

  • Residencies

    University of Texas Anderson Cancer Center, Radiation Oncology, 2007

  • Academic Title

    Professor

I am a passionate advocate for my patients in helping them achieve their best outcomes, both in health and quality of life.

Melanoma & Skin Cancer Program

Bakar Precision Cancer Medicine Building

1825 Fourth Street, Third Floor
San Francisco, CA 94158

Radiation Oncology Clinic

Mission Bay Campus - Bakar Precision Cancer Medicine Building

1825 Fourth St., First Floor, Room M2267
San Francisco, CA 94158

My reviews

4.9

Overall Experience
107 Reviews
dr Yom inspires confidence in her expertise
Explained things in a way that was easy to understand
107 Reviews
Did the doctor pay attention to your concerns
107 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
100 Reviews
Knew the important information about your medical history
107 Reviews
The provider showed respect for what you had to say
106 Reviews
The provider spent enough time with me
107 Reviews
Decorative Caduceus

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

The rate of completion of all adjuvant therapy by patients treated at the maximum tolerated dose (MTD) schedule will be determined and compared to a historical control rate of 52%.

Recruiting

Decorative Caduceus

Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer

The primary endpoint for this study is the change in number of infiltrating CD3+ T cells/ μm2 in the lung cancer tissue from before and after pembrolizumab +/- SRT, based on quantification using immunohistochemistry (IHC) and imag...

Recruiting

Share